About alto neuroscience inc - ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
ANRO At a Glance
Alto Neuroscience, Inc.
650 Castro Street
Mountain View, California 94041
| Phone | 1-650-200-0412 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -63,238,000.00 | |
| Sector | Health Technology | Employees | 68 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ANRO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.76 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.495 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.066 |
ANRO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -929,970.588 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ANRO Liquidity
| Current Ratio | 15.693 |
| Quick Ratio | 15.693 |
| Cash Ratio | 15.584 |
ANRO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -34.916 |
| Return on Equity | -41.796 |
| Return on Total Capital | -36.115 |
| Return on Invested Capital | -37.101 |
ANRO Capital Structure
| Total Debt to Total Equity | 15.851 |
| Total Debt to Total Capital | 13.682 |
| Total Debt to Total Assets | 12.972 |
| Long-Term Debt to Equity | 14.703 |
| Long-Term Debt to Total Capital | 12.691 |